Literature DB >> 31912790

Should we optimize cytotoxic therapy by dosing to neutropenia? Lessons from TAS-102.

P M Kasi1, A Grothey2.   

Abstract

Entities:  

Year:  2020        PMID： 31912790     DOI： 10.1016/j.annonc.2019.11.001

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Population pharmacokinetics of cisplatin in small cell lung cancer patients guided with informative priors.

Authors:  Jurij Aguiar Zdovc; Mihaela Vaupotič; Gregor Marolt; Lea Knez; Renata Režonja Kukec; Tanja Čufer; Tomaž Vovk; Iztok Grabnar
Journal:  Cancer Chemother Pharmacol       Date:  2022-08-20       Impact factor: 3.288

2.  Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study.

Authors:  Keigo Chida; Daisuke Kotani; Yoshiaki Nakamura; Akihito Kawazoe; Yasutoshi Kuboki; Kohei Shitara; Takashi Kojima; Hiroya Taniguchi; Jun Watanabe; Itaru Endo; Takayuki Yoshino
Journal:  Ther Adv Med Oncol       Date:  2021-04-20       Impact factor: 8.168
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.